Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Three dimensional conformational changes in the cargo protei
2021-07-13

Three-dimensional conformational changes in the cargo protein’s NES, caused by protein phosphorylation, dephosphorylation, or mutation, can regulate CRM1 binding (Craig et al., 2002, Vogt et al., 2005). Additional protein modifications such as sumoylation, ubiquitination, acetylation, and/or the bin
-
Regarding the mechanism of action
2021-07-13

Regarding the mechanism of action of CRF, several studies have shown that low doses of CRF may preferentially activate CRF1 receptors in glutamatergic projection neurons, serotoninergic neurons or glutamatergic collaterals in the medial prefrontal cortex (Vertes, 2004). Indeed, prosencephalic inacti
-
br Results br Discussion Drug resistance poses the greatest
2021-07-13

Results Discussion Drug resistance poses the greatest hurdle of achieving high efficacy with AADs in cancer patients. AAD-treated cancer patients often encounter intrinsic and evasive drug resistance that diminishes the therapeutic efficacy to only minor survival benefits in most cancer types.
-
Nevertheless two problems exist in BGCFC in practice
2021-07-13

Nevertheless, two problems exist in BGCFC in practice. The first one is that time complexity of the ID assignment algorithm presented in Section 3.1 is O(N!), which means a factorial time complexity. Because it obtains the consecutive IDs by enumerating all permutations of ID 0 to N−1, the total num
-
Our published results also show that the Y and
2021-07-13

Our published results also show that the Y2 and the Y5, but not the Y1, receptors mediate NPY-induced excitation-secretion coupling in EECs (Abdel-Samad et al., 2012). Thus, it is highly important to consider controlling ET-1 circulating level via blockade of Y2 and/or Y5 receptor activation (Abdel-
-
Case report The patient was referred to the
2021-07-13

Case report The patient was referred to the oral and maxillofacial department at the authors’ institution for further evaluation and treatment. The patient underwent tumor resection with left hemi-mandibulectomy with wide bony margins (Fig. 1A), and mandible reconstruction with fibula free flap and
-
Nevertheless because of the preclinical work and the interfe
2021-07-13

Nevertheless, because of the preclinical work and the interference with EWS–FLI1 transcriptional activity, we believe that there may be a role for ET-743 in Ewing sarcoma. An analysis of the pharmacokinetic data published in the phase II clinical trial shows that at most the drug spent 5 to 6days ou
-
In this study we also
2021-07-13

In this study, we also conducted an analysis comparing the expression profiling of Hh genes among the sarcomas investigated. In these tumors, the IHH gene showed a higher expression level than PTCH1 gene in RMS and SS samples (pspectinomycin in human RMS cell lines as well as mouse NIH-3T3 fibrobla
-
In our former work our interest was in discovery
2021-07-13

In our former work, our interest was in discovery of novel VEGFR-2 inhibitors as anti-angiogenesis agents. Along this line, with natural alkaloid taspine as the lead compound, rounds of structure optimization were performed to develop novel VEGFR-2 inhibitors [[13], [14], [15]]. Among them, BPS-7, b
-
br Results Patient disease and treatment
2021-07-13

Results Patient, disease, and treatment characteristics of the study cohort are described in Table 1. All patients were stage IIIA with pathologically documented N2 disease per AJCC 7th edition. EP4 nuclear staining 0–1 versus 2+ was significantly associated with overall survival (OS) (44.3 vs.
-
AH 6809 Although PKC in cancer cells
2021-07-12

Although PKCδ in cancer AH 6809 is known to promote antiapoptotic signaling, a cleaved form of PKCδ, δCF, has been reported to play a contrasting role in enhancing apoptosis (Reyland, 2007), and these complex functions appear to be cell-type dependent (Basu and Pal, 2010). In NSCLC, full-length PKCδ
-
Recent studies from the literature have identified
2021-07-12

Recent studies from the literature have identified new o6 methylguanine methyltransferase of antiviral agents able to target diverse host factors indispensable for efficient virus replication: as an example, the human DEAD-box polypeptide 3 (DDX3) inhibitor, 1-[4-(4-methyl-1H-1,2,3-triazol-1-yl)phen
-
br Type II NAD P H Dehydrogenases
2021-07-12

Type II NAD(P)H Dehydrogenases in Fungi Fermentative YeastSaccharomyces cerevisiaeBecause S. cerevisiae is a facultative hmg-coa reductase inhibitors yeast capable of meeting its energy requirements with ATP generated by fermentation, only relatively few mitochondrial proteins are essential for
-
The heterogeneity among studies that investigated the associ
2021-07-12

The heterogeneity among studies that investigated the association of COMT Val158Met with alexithymia was also significant (Ham et al., 2005; Min et al., 2016; Swart et al., 2011; Zekioglu et al., 2014). The healthy status, drug effect, and other demographic variables also influenced one's ability o
-
br Next let s recall some definitions and notations from
2021-07-12

Next, let's recall some definitions and notations from [14] which are necessary to obtain the proof of Theorem 1. Let denote the CMV matrix whose Verblunsky coefficients replaced by , that is The corresponding extended CMV matrix is Recall the definition of in the proof of Theorem 2, replace by
15135 records 642/1009 page Previous Next First page 上5页 641642643644645 下5页 Last page